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a b s t r a c t
Atherosclerotic plaques are cholesterol-induced inﬂammatory niches accumulating in the vascular sub-
endothelial space. Cellular and extracellular composition of human plaques is maneuvered by local
inﬂammation that leads to alterations in the original vascular microenvironment and to the recruitment
of an invading ﬁbrous layer (ﬁbroatharoma). In the present study we introduce a bioengineered three-
dimensional model of human ﬁbroatheroma (ps-plaque) assembled with a tailored hanging-drop pro-
tocol. Using vi-SNE based multidimensional ﬂow cytometry data analysis we compared the myeloid cell-
populations in ps-plaques to those in plaques isolated from human carotid arteries. We observed that
plasmacytoid and activated dendritic cells are the main myeloid components of human carotid plaques
and that both cell types are present in the biofabricated model. We found that low-density lipoproteins
affect cell viability and contribute to population polarization in ps-plaques. The current work describes
the ﬁrst human bioengineered in vitro model of late atherosclerotic lesion for the investigation of
atherosclerosis aetiopathogenesis.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Atherosclerosis is a life threatening vascular pathology charac-
terized by the accumulation of a fatty plaque in the vascular sub-
endothelial space [1]. Atherosclerotic plaque formation is inﬂu-
enced by the synergistic interplay of different risk factors such as
sex, age, genetic predisposition, high blood pressure and high blood
levels of low-density lipoprotein (LDL) cholesterol [2,3]. The for-
mation of a well-structured plaque microenvironment results from
the interplay of cholesterol-rich lipoproteins, endothelial cells,
monocytes, macrophages, dendritic cells and ﬁbroblasts in a com-
plex matrix milieu [4]. The process of plaque formation is pro-
gressive and reversible [3,5] and can be counteracted by a reduction
of the modiﬁable risk factors mentioned above or promoted by
their persistence. Plaques are classiﬁed according to their stage of
development and cellular components [4]. Among different plaque
stages, the thin-cap ﬁbroatheroma is the one most prone to rupture
and to potentially cause thrombus formation and vessel obstruction
[6]. The ﬁbroatheroma is characterized by the presence of a necrotic
core, macrophage-derived foam cells and dendritic cells all being
enriched with cholesterol and embedded in a collagenous matrix
surrounded by a thin layer of ﬁbrotic cells [4,5]. The cellular
mechanisms underlying plaque formation and regression have
been investigated in vivo in both small and large animals, pre-
dominantly in hypercholesterolemic mice with knock-out of either
Apoe or LDL-receptor [7e9] or non-human primates [10,11].
Despite the stunning contribution to the ﬁeld, major differences in
anatomy, lipoprotein proﬁles and inﬂammatory mechanisms
hampered the translation of these results to the human patho-
physiology. To overcome the translational gap, human cell-based
co-culture in vitro models have been established and provided a
ﬁrst glimpse into the initial events of plaque deposition in humans
[12e15]. To our knowledge, no human model of late stages of
atherosclerotic plaque development does exist. In the present study
we introduce a bioengineered in vitro model of ﬁbroatheroma that
we call pseudo plaque (ps-plaque). The ps-plaque architecture is
characterized by a spheroid core of monocytes, macrophages and
dendritic cells embedded in a collagenous and lipid-rich matrix,
surrounded by a thin layer of myoﬁbroblasts. In order to investigate
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a possible source for model up-scaling we biofabricated ps-plaques
using either blood-derived myeloid cells or cells from the thp-1 cell
line. We explored the similarities in surface antigen expression
patterns of myeloid populations from ps-plaques and human ca-
rotid plaques isolated from patients undergoing carotid endarter-
ectomy. Additionally, we compared the expression levels of key
pro-inﬂammatory and remodeling gene-targets in both plaque
types. We found similarities in population distribution and gene
expression proﬁles between ps-plaques and human samples.
Finally, we used the ps-plaque to investigate the role of LDL in
plaque population remodeling and cell viability. With this work we
introduce a new technology for investigating atherosclerosis
pathomechanisms, aiming at providing a novel human cell-based
platform for drug design and high-throughput screening.
2. Materials and methods
2.1. Isolation of myeloid cells from blood
Myeloid cells were isolated from human blood using a double
gradient centrifugation. The blood was provided by the Zurich
blood bank (Blutspende Zürich e Nr.6676) and maintained at room
temperature in slow rocking motion until processing. First, 20 ml of
blood from each donor were diluted 1:2 with 1  Phosphate Buffer
Saline (PBS, Sigma) at room temperature and layered onto a Ficoll
solution (1.077 g/ml, Sigma). Samples were then centrifuged at
400 g for 30min without break. Second, a 46% iso-osmotic Percoll
gradient was performed to separate the lymphocytes from the
peripheral blood mononuclear cells (PBMCs) as previously
described [16]. Brieﬂy, the buffy coat was re-suspended in 20 ml of
xVivo15 chemically deﬁned medium (Lonza) without red phenol
and carefully layered on top of a Percoll solution prepared with 50%
Roswell Park Memorial Institute (RPMI) medium with red phenol
(Sigma), 46% Percoll (GE Healthcare) and 4% 1  PBS (Sigma). The
second gradient was centrifuged at 550 g for 30min without break
and the white cell ring at the interphase was collected for further
processing.
2.2. Myoﬁbroblasts isolation
Human umbilical vein myoﬁbrobalsts (HUVM) were isolated
from human umbilical cords. The tissues were processed in accor-
dance to the ethical permit released by the Kantonale Ethikkom-
mission Zürich (KEK-Stv-21-2006). Brieﬂy, umbilical cords were
stored after labor at 4 C in Dulbecco's Modiﬁed Eagle's Medium
(DMEM, Sigma) prepared with 10% Fetal Bovine Serum (FBS, Gibco),
1% GlutaMax (Gibco) and 1% penicillin/streptomycin (Penn/Strep,
Gibco) for maximum 2 h prior to processing. The umbilical veinwas
carefully extracted from the umbilical cord and the inner lumen
was ﬂashed twice with 1  PBS. The adventitia layer was peeled off
with the help of forceps and scalpel. The intima layer was removed
by incubating the inner lumen for 30min in a 1 mg/ml collagenase/
dispase (Roche) solution in 1 PBS. The remaining endothelial cells
were washed out from the lumen with 1  PBS. The remaining
media layer was minced into small pieces of approximately 2 mm
length and let adhere for 10min on the bottom of a petri dish. The
tunica media fragments were then covered in DMEM medium and
maintained at 37 C, 5% CO2 and 95% humidity. The medium was
replaced every 48 h. After about 20 days myoﬁbroblasts sprouting
from the minced pieces reached about 80% conﬂuence and were
ready for sub-culturing.
2.3. Cell culture
HUVM were cultured in DMEM medium with 10% FBS and 1%
GlutaMax and the medium was replaced every 48e72 h. For sub-
culturing, HUVM were detached using trypsin 0.5% (Sigma) for
4 min and seeded at a cell density of 4000 cells/cm2. HUVM were
expanded up to passage 5 prior to use for the experiments in this
study. Human monocytic leukaemia cell line (thp-1) isolated from
the peripheral blood of a 1-year-old human male with acute
monocytic leukemia, were purchased from Sigma. Thp-1 cells were
cultured in suspension in xVivo15 medium and the medium was
replaced every 2e3 days. Thp-1 cells were seeded at a density of
100,000 cells/ml and sub-cultured at a density of 800,000 cells/ml.
2.4. Ps-plaque biofabrication
The pseudo-plaque production pipeline encompasses three
steps: differentiation, priming and hanging-drop. First, fresh blood-
derived myeloid cells or thp-1 cells were seeded onto petri dishes
for 72 h and differentiated in chemically deﬁned xVivo15 medium
with 10% FBS in order to achieve a macrophage/dendritic cell
phenotype. To induce thp-1 differentiation 10 ng/ml of phorbol 12-
myristate 13-acetate (PMA, Sigma) were added to the culture me-
dium. Second, a priming step was performed to obtain heteroge-
neous macrophage/dendritic cell populations with both pro-
inﬂammatory and remodeling phenotypes. For this purpose the
differentiated cells were rinsed in 1  PBS and treated for 1 h in
xVivo15 medium with 10% FBS and 10 ng/ml lipopolysaccharide
(LPS, Sigma). Finally, the primed cells were transferred in hanging-
drop culture. Brieﬂy, adhesive myeloid-derived cells were me-
chanically detached by 20min incubation in 5 mM Ethyl-
enediaminetetraacetic acid (EDTA, Life Technologies) in 1  PBS at
4 C and gentle scraping. Cells were re-suspended at a cell density
of 2.4  106 cells/ml in presence of LDL 50 mg/ml (LEE Biosolutions)
in xVivo15 medium with 10% FBS. Droplets of 10 ml were pipetted
on the lead of a 10 cm diameter petri dish and kept in hanging-drop
culture for 48 h. To the core of myeloid-derived cells assembled
during the 48 h incubation, an external layer of HUVM was added.
HUVMwere prepared at a cell density of 4  105 cells/ml in DMEM
medium, with or without 50 mg/ml LDL. 10 ml of the cell suspension
were carefully added to each pre-existing drop and cultured in
hanging-drop for further 48 h.
2.5. 2D co-culture
Primed myeloid cells from blood or thp-1 origin were seeded in
24 well plates maintaining the same cell ratio used for the ps-
plaque biofabrication (myeloid cells:myoﬁbroblasts 6:1). In detail,
about 3000000 primed myeloid cells were seeded with or without
50 mg/ml LDL in each well in order to achieve a conﬂuent cell layer.
Cells were kept in xVivo15 mediumwith 10% FCS and in 2D culture
for 48 h. 500000 ﬁbroblasts/well in DMEM medium (with or
without 50 mg/ml LDL) were then added on top of the myeloid cell
layer and incubated for 48 h to obtain a stratiﬁed 2D co-culture
system.
2.6. Flow cytometry
Biopsies of carotid branches were obtained from patients un-
dergoing carotid endarterectomy and shunting, secondary to
vascular stenosis (Ethik Kommission der Universit€at Witten/Her-
decke e Nr.79/2012). Carotid plaques and biofabricated ps-plaques
were digested with 1 mg/ml collagenase/dispase solution in
1 PBS for 15min at 37 C. Cells were gently pipetted through a cell
strainer with the mesh size of 40 mm (Falcon) and incubated for
5 min at 4 C with magnetic beads coated with anti CD45 anti-
bodies, according to the provider instructions (MACS Miltenyi
Biotec). CD45 þ cells were magnetically sorted and stained with
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Zombie Aqua™ ﬁxable viability kit (BioLegend) for 5min and ﬁxed
over night at 4 C in a 1% Paraformaldehyde (PFA, Sigma) solution in
1  PBS. The single cell suspension was stained for 15 min at room
temperature in Fluorescence-activated cell sorting (FACS) buffer
prepared with 5% FBS and 0.01% NaN3 (Sigma) in 1  PBS with an
optimized FACS antibody panel including: CD14-PerCP (#325631,
Biolegend), CD16-Alexa 700 (#360717, Biolegend), CD11b-Alexa594
(#101254, Bioloegend), CD11c-PE-Cy5 (#301609, Biolegend), CD36-
BV605 (#563518, Becton Dickinson) and SRA-1-PE (#REA460,
MACS Miltenyi Biotec). Each antibody was previously titrated to
establish the optimal working concentration. Samples were ac-
quired using LSR Fortessa analyzer (Becton Dickinson) and signal
compensation was performed using OneComp eBeads
(eBioscience).
2.7. vi-SNE workﬂow
The Flow Cytometry Standard (FCS) ﬁles obtained from the FACS
analysis were pre-processed using the software Flowjo (FlowJo,
LLC). First, the cell populations of interest were gated according to
forward and side scatter parameters (FSC and SSC). Second, singlets
and Zombie Aqua™ dye negative events were selected, represent-
ing the living cell population of interest. Data post-processing was
performed using the R platform and the Cytofkit package. Brieﬂy,
pre-processed FCS ﬁles from each sample were loaded onto
Cytofkit, randomly down-sampled to 2000 events (ceil; n ¼ 2000)
and computed using t-Distributed Stochastic Neighbor Embedding
(t-SNE) algorithm [17]. Each event recorded was positioned in a
speciﬁc location of the high-dimensional space. The output was a
vi-SNE biaxial plot where distances between events are represen-
tatives of cell proximity in high-dimensional rather than two-
dimensional space. The proximity between events is based on
similarities in surface marker expression levels. Different myeloid
subsets were positioned in separate regions in high-dimensional
space according to surface marker similarities. Automatic gating
of myeloid subsets was performed through a preliminary clustering
step with PhenoGraph algorithm (k ¼ 42) and a following meta-
clustering step with FlowSOM algorithm (k¼ 10). The output of the
above-described vi-SNE workﬂow is a vi-SNE map for each sample
originally analyzed using FACS. Different biological replicates from
each sample are combined to obtain a cumulative vi-SNE map.
2.8. Immunoﬂuorescence
Myoﬁbroblasts were ﬁxed for 20min in 4% PFA in 1  PBS and
maintained in 1 PBS at 4 C until further processing and not more
than 7 days. Cells were stained with the primary antibodies anti-
alpha smooth muscle actin (aSMA, #ab7817, Abcam) and anti-
smooth muscle myosin heavy chain (SMMHC, #ab53219, Abcam)
overnight at 4 C andwith secondary antibodies (anti-mouse #715-
605-151, Jackson Immuno Research; anti-rabbit #A11008, Life
Technologies) and phalloidin (#A12381, Life technologies) for 1 h at
37 C. Nuclei were counterstained with DAPI and the slides were
mounted in Vectaschield® (Vector Laboratories). The ps-plaques
were carefully washed in 1  PBS and ﬁxed in PFA as described
above. Plaques were dehydrated overnight in a solution of 25%
sucrose (Sigma) in 1 PBS, embedded in OCTmatrix (CellPath) and
stored at 20 C. Slices of 5 mmwere cut, rehydrated in 1  PBS for
15min and stained with primary antibodies: anti-Collagen type III
(#ab7778, Abcam), anti-aSMA and anti-CD45-PeCy5 (#304009,
BioLegend) overnight at 4 C. Secondary antibody staining was
performed (anti-mouse, 715-545-151, Jackson Immuno Research;
anti-rabbit #A11008, Life Technologies) for 1 h at 37 C. For the
Filippin sections were quenched for 10min with 1.5 mg/ml glycine
(Sigma) in 1  PBS prior to addition of 250 mg/ml Filippin III dye
(Sigma) at room temperature for 2 h. Sections werewashed 3 times
in 1  PBS and nuclei were counterstained with propidium iodide
1 mg/ml (BioLegend) for 5min. Slides were mounted in Vecta-
schield®. Images were acquired in grey scale with the confocal
microscope (Leica SP8). Image post-processing, speciﬁcally the
choice of appropriate pseudo-colors, was performed using ImageJ.
2.9. RT-qPCR
Total RNA was extracted using the GenElute Mammalian Total
RNA Kit (Sigma), following themanufacturer's instructions. Reverse
transcription was performed for each sample in a 20 ml reaction
mixture containing 1 mg of RNA, 1  PCR buffer, 5 mM MgCl2,
10 mM of each dNTP, 0.625 mM oligo d(T)16, 1.875 mM random
hexamers, 20U RNase inhibitor and 50UMuLV reverse transcriptase
(all from Life Technologies). The conditions for the reverse tran-
scription were the following: 25 C for 10min, 42 C for 1 h, fol-
lowed by 99 C for 5min. The resulting cDNA was ampliﬁed in
duplicate by quantitative real-time PCR in 10 ml reaction mixture
with 200 nM of each speciﬁc primer (Supplementary Table 2) and
1 Fast Syber Green qPCRMasterMix (Applied Biosystems). For the
ampliﬁcation reaction, StudioQuant 7 was used (Applied Bio-
system). The ampliﬁcation program was set as follows: 95 C for
5min, followed by 40 cycles at 95 C for 10 s, 60 C for 15 s, 72 C for
20 s. GAPDH and 18S served as housekeeping genes and their
ampliﬁcation data were averaged and used for sample normaliza-
tion. The software Excel (Microsoft) was used for the comparative
quantiﬁcation analysis.
2.10. Ps-plaque viability assay
Cell viability within the plaque was measured using CellTiter-
Glo® 3D Cell Viability Assay (Promega). Brieﬂy, the biofabricated
plaques were washed in 1  PBS and dispensed in a opaque-walled
96 well plate (Costar). Each ps-plaque (1 plaque/well) was
dispensed in 15 ml of 1  PBS. Equal volume of CellTiter-Glo® 3D
Reagent was added to each well for a ﬁnal volume of 30 ml. Lumi-
nescence was measured after a 30min of incubation at room tem-
perature with SPECTRAmax® Gemini-XS (Bucher biotech) and ATP
levels were reported in relative luminescence units (RLU).
2.11. Quantiﬁcation of ps-plaque area and necrotic area
For the measure of the plaque necrotic area, every plaque was
stained for 40min in a solution of calcein (5 mM) and eth-1 (15 mM)
from the LIVE/DEAD™ Viability/Cytotoxicity Kit, for mammalian
cells (Life Technologies). Ps-plaques were imaged using an inverted
microscope (Leica, DM IL LED) and post-processed in ImageJ.
Brieﬂy, images underwent color 2D Parallel iterative deconvolution
using the Wiener Filter Preconditioned Landweber (WPL) method
(Max number of iteration ¼ 5; Max number of threads2 ¼ 4). The
results of the point of spread function obtained from the decon-
volution were normalized and the green and red channels were
thresholded with the MaxEntropy setting. The ps-plaque necrotic
area was measured as necrotic area over alive area and indicated as
percentage. Plaque dimension was measured using the bright ﬁeld
images of the plaque circular cross section. First, the image was
converted to 8-bit format and thresholded with the MaxEntropy
method. Second, the area of the particles was analyzed from objects
with a dimension larger than 1,000px in order to exclude debris or
single cells not belonging to the bioengineered plaque. Plaque area
was reported in mm2.
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2.12. Statistical analysis
vi-SNE cluster counts and PCR comparative quantitations were
analyzed using multiple comparison analysis. First, Gaussian dis-
tribution of the data was conﬁrmed with Shapiro-Wilk normality
test. Second, repeated measures (RM) two-way ANOVA with
Tukey's multiple comparison test was applied. Luminescence and
necrotic area were analyzed with paired t-test. All statistical ana-
lyses were performed with GraphPad Prism Version 7, GraphPad
Software, San Diego, CA, USA). Signiﬁcance was accepted at
p < 0.05. All data are presented as mean ± s.d..
Fig. 1. Biofabricated human atherosclerotic plaque. (a) Schematic view of the ps-plaque assembly with blood-derived cells. (b) Expression proﬁle of pro-inﬂammatory (left-white
panel) and remodeling genes (right-orange panel) over the differentiation-priming process. Data are reported in fold change over gene expression levels at the beginning of the
differentiation-priming process. N ¼ 5; error bars indicate standard deviation; *p ¼ 0.05, ***p < 0.001. (c) vi-SNE maps indicating the cell populations at the beginning (Mo) and at
the end (pMf/d) of the differentiation-priming process. N ¼ 7; 2000 events per sample are reported; 14,000 events are shown in each vi-SNE map. The stacked-bar chart indicates
the percentage of events recorded in each population and summarizes the vi-SNE results. (d) Representative cross-section captured at the great circle of the spheroid showing inner
architecture of the ps-plaque: HUVM (aSMAþ, green) and myeloid cells (CD45þ, magenta). Scale bar 100 mm. (e) Collagen III and lipid accumulation in the ps-plaque. Scale bar
50 mm.
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3. Results
3.1. Differentiation-priming strategy promotes population
redistribution in cells from myeloid origin
We established a two-step bioengineering method for the as-
sembly of the ps-plaque (Fig.1a). Myeloid cells isolated from freshly
drawn blood and thp-1 cells were differentiated towards macro-
phage/dendritic phenotype and primed with LPS to obtain a mixed
population of pro-inﬂammatory and remodeling cell populations.
The success of the differentiation-priming strategy was veriﬁed
using a ﬂuorescence-activated cell sorting (FACS) and the results
were computed using dimensionality reduction and clustering al-
gorithms, PhenoGraph and FlowSOM respectively [18]. With this
technique we identiﬁed 15 cell populations in the multidimen-
sional space that we classiﬁed according to the differential
expression levels of key surface markers (Fig. 1c; Supplementary
Fig. 1; Supplementary Fig. 2 and Supplementary Table 1). In sam-
ples isolated from the blood we identiﬁed 4 over-represented
populations: classical monocytes (Mocl), macrophages (M41), pre-
classical dendritic cells (pre-cDC) and an unknown myeloid pro-
genitor population (Prog) (Fig. 1c; Supplementary Fig. 2). We
monitored each population at the end of the differentiation-
priming process and we observed a signiﬁcant decrease in the
unknown myeloid progenitors (p ¼ 0.005) coupled with a signiﬁ-
cant increase in pre-cDC (p ¼ 0.05) (Fig. 1c). Additionally, we
observed a priming-induced increase in CD11c surface levels within
the pre-cDC population and in the myeloid progenitors
(Supplementary Fig. 3, Supplementary Fig. 4). In cell samples from
untreated thp-1 we observed an initial population distribution
similar to the one found in blood samples. When we applied the
priming process to thp-1 monocytes, we observed a signiﬁcant
reduction in the myeloid progenitors count (p < 0.001). The latter
was concomitant with a decrease in pre-cDC count (p < 0.001) and
Fig. 2. Comparison between biofabricated plaques and human carotid plaques. (a) vi-SNE maps from CD45 þ populations isolated from blood-derived plaques (b-plaques), thp1
plaques (t-plaques) and carotid plaques. N ¼ 7; 2000 events per sample are reported. A total of 14,000 events are shown in each vi-SNE map. (b) The stacked-bar chart summarizes
the percentage of events for each population. (c) Gene expression proﬁle of CD45 þ populations isolated from ps-plaques and plaques from carotid arteries. Expression levels of
remodeling genes (upper panel) and pro-inﬂammatory genes (lower panel). N ¼ 5, error bars indicate standard deviation. **p ¼ 0.002, ***p < 0.001.
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the appearance of plasmacytoid dendritic cells (PDC)
(Supplementary Fig. 5, Supplementary Fig. 6, Supplementary
Fig. 7). Furthermore, we observed that the priming process trig-
gered the proliferation of classical monocytes (p < 0.001)
(Supplementary Fig. 5). We then analyzed the expression levels of
pro-inﬂammatory and remodeling gene targets. In blood derived
cells we observed induction of CXCL10 (p < 0.001), CCL17 (p < 0.05),
DC-SIGN (p < 0.001) and SRB1 (p < 0.001) upon treatment, indi-
cating the overall stronger induction of remodeling over pro-
inﬂammatory genes (Fig. 1b). When we analyzed the changes in
thp-1 cells gene expression levels upon differentiation-priming we
observed induction of CXCL10 (p ¼ 0.03), PTGS1 (p ¼ 0.05) and IL10
(p ¼ 0.01), indicating pro-inﬂammatory gene up-regulation over
remodeling genes (Supplementary Fig. 8).
3.2. Deﬁning the gravity-guided biofabrication of human
atherosclerotic plaques
Human primed myeloid cells and myoﬁbroblasts (HUVM) were
combined to establish a hanging-drop 3D co-culture system
(Fig. 1a; Supplementary Fig. 9). The newly established system
resulted in a-SMA þ HUVM cells surrounding pre-existing myeloid
CD45 þ cell aggregates and forming a thin ﬁbrotic layer around the
bioengineered spheroid (Fig. 1d). The generation of such stratiﬁed
structure and compact HUVM layer was not observed in 2D co-
culture systems when using the same cell-to-cell ratio
(Supplementary Fig. 10). Additionally, we observed the assembly of
collagen clumps within the ps-plaque and intra-plaque accumula-
tion of lipid aggregates (Fig. 1e). We did not detect any extracellular
collagen deposition in 2D co-culture systems. Collagen was rather
retained in the intracellular space (Supplementary Fig. 10).
3.3. vi-SNE analysis reveals plasmacytoid and activated dendritic
cells as main myeloid components in human ﬁbroatheroma
To corroborate the ps-plaquemodel we conducted a comparison
study between bioengineered and human atherosclerotic plaques
isolated from patients that underwent carotid endarterectomy. We
Fig. 3. LDL effects on myeloid cells isolated from b-plaques. (a) vi-SNE maps indicating myeloid populations identiﬁed within b-plaques biofabricated either using LDL-enriched
(LDL) or LDL-free (w/o LDL) medium. The stacked-bar chart summarizes the results from the vi-SNE maps and reports the percentage of events recorded in each population. (b)
Event density distribution vi-SNE maps show high-density (red) and low-density of events (blue) areas. (c) Marker expression level vi-SNE plots. N ¼ 7; 2000 events per sample are
reported; 14,000 events are displayed in the vi-SNE maps in a and b. vi-SNE maps in c are generated using 2000 events from all samples.
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observed large similarities in population distribution within b-
plaques and t-plaques. In detail, we found that the main cell pop-
ulations are classical monocytes, macrophages, activated dendritic
cells and plasmacytoid dendritic cells (Fig. 2a and b;
Supplementary Fig. 11). When we analyzed CD45 þ cells from ca-
rotid plaques, we identiﬁed PDC and aDC populations as main
myeloid plaque components (Fig. 2a and b; Supplementary Fig. 12).
We further investigated the event density distribution within the
PDC populations in human carotid plaques. We identiﬁed 3 major
areas of the vi-SNE map corresponding to peculiar PDC phenotypes
that we classiﬁed as a, b and g (Supplementary Fig. 12). PDC type-a
represents a relatively small cluster with phagocytic and lipopro-
tein clearance predisposition due to high surface levels of scavenger
receptors CD36, SRA-1 and CD14. PDC type-b is a larger cell cluster
characterized by CD16high, indicating a possible involvement in pro-
inﬂammatory reactions. PDC type-g appears to be exclusively
specialized in lipid and lipoprotein uptake, provided the predom-
inant surface expression levels of CD36 (Supplementary Fig. 12).
Interestingly, in both bioengineered plaque models (b- and t-pla-
ques) we identify PDC Type-b (Supplementary Fig. 11). Finally, we
analyzed the gene expression proﬁle of the CD45 þ populations in
ps-plaques and carotid plaques. We reported a signiﬁcant down-
regulation of pro-inﬂammatory and remodeling gene targets in
carotid plaques compared to bioengineered plaques (Fig. 2c).
3.4. Low-density lipoprotein promotes the differentiation of a
precursor myeloid population in biofabricated plaques
We investigated the effects of LDL on the differentiation of
myeloid (CD45þ) subpopulations isolated from b- and t-plaques. To
do so, we biofabricated ps-plaques using either the established
protocol based on LDL-enriched medium or using LDL-free me-
dium. We applied the vi-SNE workﬂow to compare the respective
cell populations. In b-plaques we observed a reduced count of
precursors in LDL-enriched versus LDL-free controls (p < 0.001,
Fig. 3a, Supplementary Fig. 13) suggesting differentiation triggered
by LDL. The difference in precursor counts can also be appreciated
in the respective density plots (Fig. 3b, Supplementary Fig. 13).
Additionally, we compared vi-SNE density plots from ps-plaques
biofabricated in LDL-rich and LDL-free medium. To investigate
variations in LDL triggered surface antigen expression within each
population we overlapped the density plots with the marker
expression level plot. We observed an LDL dependent density shift
in aDC towards vi-SNE areas with CD11chigh, CD16high and CD36high
expression levels (Fig. 3b and c). In t-plaques, we observed an LDL
dependent density shift of M41 towards CD36high and CD11chigh
areas of the vi-SNEmap and of Mocl towards a CD36high vi-SNE area
(Supplementary Fig. 14; Supplementary Fig. 15, Supplementary
Fig. 16).
3.5. The hanging-drop environment allows the establishment of a
pro-inﬂammatory niche
To uncover possible transcriptional effects exerted by LDL on key
target genes, we investigated the expression proﬁles of the myeloid
component during two steps of the ps-plaque biofabrication: (i)
after 48 h in hanging-drop (T1) and (ii) at the end of the hanging-
drop process (T2). We compared T1 and T2 from ps-plaques pro-
duced in LDL-free or LDL-enriched environment. Surprisingly,
despite the induction of dendritic cell-speciﬁc intercellular adhe-
sion molecule DC-SIGN (p < 0.001 versus p ¼ 0.003, Fig. 4a) we did
not ﬁnd any signiﬁcant LDL-dependent transcriptional change in b-
plaques and t-plaques over time (Fig. 4a; Supplementary Fig. 17).
On the other hand, we found that the hanging-drop process had,
per se, a major inﬂuence on the gene expression levels by directly or
indirectly promoting the establishment of a pro-inﬂammatory
environment. In detail, in b-plaques we observed a signiﬁcant
down-regulation of CCL26 (p < 0.001) and up-regulation of key pro-
inﬂammatory genes CXCL10, CCR7 and IL23 (p < 0.001) during the
transition from T1 to T2 and independently from the presence of
LDL (Fig. 4a). We observed an indirect pro-inﬂammatory effect in t-
plaques, exerted through the down-regulation of the anti-
inﬂammatory cytokines CCL26, IL10 and CCL17 (p < 0.001,
Supplementary Fig. 17). We validated these observations perform-
ing a control experiment in which we investigated the gene
expression proﬁle of CD45 þ cells using a 2D co-culture approach
(Supplementary Fig. 10a). As for the hanging drop approach, we
performed the transcriptomic analysis over time (T1 and T2) in
LDL-free and LDL-enriched medium, using both blood-derived and
thp-1 cells (Supplementary Fig. 18). When we investigated the
transcripts proﬁle of blood-derived cells co-cultured in 2D we did
not observe any time-dependent pro-inﬂammatory effect apart
from the down-regulation of CD26 (p ¼ 0.006 in LDL-rich condi-
tion; p < 0.001 in LDL-free condition). When we repeated the
experiment using thp-1 co-cultured in 2D, not only we did not ﬁnd
any time-dependent pro-inﬂammatory effect but also we reported
a signiﬁcant time-dependent anti-inﬂammatory effect achieved
with the down-regulation of two pro-inﬂammatory markers:
PTGS1 and ALOX5 (both p < 0.001, Supplementary Fig. 18).
3.6. Low-density lipoprotein enhances cell death in ps-plaques
biofabricated with primed blood cells
To further explore the effects of LDL on the ps-plaque model we
conducted a bivalent analysis. First, we investigated the cell
viability within the ps-plaque.Wemeasured and compared the ATP
levels produced by the biofabricated plaques in LDL-enriched and
LDL-free medium. We did not ﬁnd any signiﬁcant LDL-dependent
differences in ATP levels in either b- or t-plaques (Fig. 4b). How-
ever, we observed a general tendency of lower ATP levels in plaques
produced in LDL-rich environments. We then measured the
necrotic area at the circular cross-section and we found that b-
plaques fabricated in presence of LDL had a signiﬁcantly larger
necrotic area in comparison to their LDL-free counterparts, sug-
gesting an LDL-dependent necrotic effect (p < 0.001, Fig. 4d and e).
Second, we investigated differences in plaque dimensions to verify
possible effects of LDL on cell proliferation. We found no difference
in circular cross-section area e consequently in size e of LDL-
enriched vs LDL-free plaques (Fig. 4c).
4. Discussion
With the biofabrication of the ps-plaquewe aimed at replicating
cellular architecture and extracellular microenvironment of a hu-
man atherosclerotic plaque to close an open modeling gap in the
ﬁeld of atherosclerosis research. It has been described that the
ﬁbroatheroma cellular composition is mainly characterized by
macrophages and dendritic cells retaining pro-inﬂammatory and
remodeling abilities [19e21]. To achieve plaque cell populations as
similar as possible to human atherosclerotic plaque phenotypes we
established a differentiation-priming protocol based on a mild LPS
stimulation of cultured adhesive myeloid cells [22,23]. To visualize
and quantify the effects of this procedure on cell population
remodeling we used the vi-SNE workﬂow [18,24,25]. With this
strategy we identiﬁed a total of 15 cell populations, differently
distributed among samples. We were able to classify these pop-
ulations according to the prevalence of speciﬁc surface markers
[26,27]. We were also able to track intra-population density shifts
and changes in numbers of events. The sensitivity of the vi-SNE
analysis allowed the identiﬁcation of under-represented myeloid
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populations, otherwise difﬁcult to identify with commonly used
ﬂow cytometry analysis tools. Thanks to the vi-SNE workﬂow we
identiﬁed in blood-derived myeloid samples both plasmacytoid
dendritic cells (PDC) and pre-classical dendritic cells (pre-cDCs)
[27].
The vi-SNE analysis reported a yet unidentiﬁed myeloid popu-
lation in both thp-1 and blood derived samples. We observed a
signiﬁcant decrease of this population upon differentiation-
priming treatment in both blood-derived and thp-1 samples. The
decreasewas concomitant to a signiﬁcant increase in pre-cDC count
in blood-derived samples and to an increase in PDC in thp-1 sam-
ples. Based on the current myeloid differentiation map [19,27] and
on our observations we propose that the yet unidentiﬁed
population could be classiﬁed as a circulating common precursor of
pre-cDC and PDC, differentiating from the common dendritic cell
precursors located in the bone marrow (Supplementary Fig. 19).
Further investigation on this cell population could improve un-
derstanding and redesigning of the myeloid differentiation map.
Primed cells and myoﬁbroblasts were used for ps-plaque bio-
fabrication and were combined to generate a stratiﬁed cell-
spheroid with myoﬁbroblasts located at the periphery and a
compact, collagenous and lipid-rich core of CD45 þ cells. We sorted
and compared the CD45 þ populations derived fromps-plaques and
native human carotid plaques using qPCR and the vi-SNE workﬂow.
First, we compared the gene expression of CD45 þ cells isolated
from ps-plaques and native plaques and we reported major
Fig. 4. Transcript analysis of pro- and anti-inﬂammatory gene targets in b-plaques and LDL effects on cell viability and plaque dimension. (a) Heat-map indicating the
expression levels of target genes of interest at T1 and T2 of b-plaque formation in LDL presence (T1L, T2L) or absence (T1, T2). Expression levels are reported in DCt over the mean of
the housekeeping genes GAPDH and 18S; n ¼ 5. (b) ATP levels, indicated in relative luminescence units (RLU), were measured and compared in b- and t-plaques; n ¼ 5. (c) Plaque
circular cross-section area (mm2) as indicator of plaque dimension; n ¼ 5. (dee) The ps-plaque necrotic area was measured at the circular cross-section at the great circle of the
spheroid, and indicated as percentage over alive cells. Living cells (green) are stained with calcein while dead cells (red) with Eth-1; n ¼ 5, ***p < 0.001, scale bar 100 mm.
A. Mallone et al. / Biomaterials 150 (2018) 49e5956
differences in transcripts level. Second, we investigated and
compared the cell populations between ps-plaques and native
plaques and we found that PDC and activated dendritic cells (aDC)
are the main myeloid component of thin-cap stage atherosclerotic
plaques. This ﬁnding is per se surprising provided thatmacrophages
and macrophage-derived foam cells are thought to be the main
cellular component of atherosclerotic lesions, at least in early
developmental stages, as discussed by Moore and Randolph
[28,29]. Importantly, both PDC and aDC are present in the bio-
fabricated models although in low percentages. It is possible that
the differences found in both gene expression and cell composition
when comparing ps-plaques and carotid plaques are due to dif-
ferences in the temporal and developmental stages of both plaque
types.
Bonanno et al. previously analyzed the cell component of hu-
man carotid plaques using ﬂow cytometry showing that about 17%
of the lesion (considering cells of lymphoid and myeloid origin and
smooth muscle cells) is constituted by CD68 þ cells [30]. They also
reported that about 40% of the cells within the plaque expressed
MHC class II molecules (HLA-DRþ) suggesting that these pop-
ulations could act as antigen-presenting cells [30]. It was also
proven that early-committed immature DCs are positive for CD68
and HLA-DR markers [31], supporting the idea that the cells
analyzed by Bonanno et al. might have been in part PDC and acti-
vated dendritic cells. Additionally, it is known that PDC aggravate
atherosclerotic lesion formation and that their depletion reduces
aortic plaque growth by 46% in Apoe/ mice [32,33]. PDC are also
able to uptake oxidized LDL (ox-LDL) ex vivo, and promote PDC-
driven antigen-speciﬁc T-cell proliferation [32]. Finally, it was re-
ported that PDC function and cytokine release is impaired in pa-
tients suffering from coronary artery disease [34,35]. Taken
together, these discoveries are in line with our ﬁndings and might
change the scenario of future atherosclerosis treatments.
Within the PDC population we identiﬁed 3 overrepresented
sub-populations that we named type-a, type- b and type-g. We
observed that these subpopulations retain some degree of
specialization due to differential marker expression levels. This
difference could be the basis of a differential contribution to plaque
maturation. For instance, PDC type-a display surface marker
expression levels (CD36high, CD14high and SRA-1high) of a special-
ized scavenger population [36]. With the ps-plaque model wewere
able to investigate LDL effects on intra-plaque population remod-
eling and cell viability. In detail, we monitored LDL-dependent
event density shift within the PDC population towards PDC type-
b phenotype. This shift was not concomitant with the increase in
the PDC count implying a PDC polarization towards CD36high and
CD16high vi-SNE regions and indicating a possible LDL-triggered
acquisition from PDC of scavenger and pro-inﬂammatory pheno-
type. Additionally, we found that LDL presence during ps-plaque
formation signiﬁcantly decreased the count of dendritic pre-
cursors in both b- and t-plaques and triggered the polarization of
aDCs towards CD11chigh, CD16high and CD36high levels. These ﬁnd-
ings are supported by the previous observations that LDL and
mildly oxidized LDL affect DC maturation and promote pro-
inﬂammatory function [37e39].
We observed an LDL-dependent decrease of plaque cell viability
in b-plaques but not in t-plaques. It was shown that LDL and ox-LDL
accumulate in the cytoplasm of the phagocyte and ultimately
contribute to a deregulation of lipid metabolism by activating the
unfolded protein response (UPR), leading to cell death [40]. The
non-signiﬁcant decrease in cell viability observed in t-plaques
might be due to intrinsic differences in population counts among
ps-plaque types. In fact, t-plaques show higher intermediate
monocyte counts when compared to b-plaques. Furthermore, b-
plaques display a larger population of activated dendritic cells
compared to t-plaques. In summary, t-plaques are constituted by a
more immature cellular milieu compared to b-plaques. For this
reason we hypothesize that populations within t-plaques would
require more time to develop towards a death-susceptible stage in
presence of LDL.
We investigated time-dependent effects of LDL on the expres-
sion proﬁle of myeloid cells within the biofabricated plaque. We
found no signiﬁcant difference in transcript levels of selected pro-
inﬂammatory and remodeling target genes [41] comparing LDL-
rich and LDL-free plaques. LDL effects on myeloid cell tran-
scriptome were previously investigated by exposing the cells
directly in contact with modiﬁed forms of LDL and not by directly
testing native lipoproteins [42,43]. However, native LDL might
retain slower time of action at the transcriptomic level compared to
its modiﬁed counterparts, as previously observed [44]. Interest-
ingly, we detected time-dependent gene induction leading to pro-
inﬂammatory cell phenotype independently from LDL treatment.
The latter was either prompted by direct up-regulation of pro-
inﬂammatory target genes in b-plaques (CXCL10, CCR7, IL23,
PTGS1) or indirectly triggered by down-regulation of anti-
inﬂammatory genes in t-plaques (CCL17, CCL26, IL10). It was
recently shown that three-dimensional spheroid cultures of
adipose-derived mesenchymal stem cells (MSC) enhance protein
levels of the anti-inﬂammatory tumor necrosis factor alpha stim-
ulated gene/protein 6 (TGS-6) [45]. On the other hand, the study
conducted by Bartosh et al. did not include any test to verify the
possible concomitant release of pro-inﬂammatory proteins, leaving
an unanswered question open for further investigations.
In conclusion, the ps-plaque is assembled with myeloid cell
populations that are shared with human native plaques. These cells
are embedded in a collagenous and lipid-rich extracellular matrix
surrounded by a ﬁbrotic layer. To our knowledge the ps-plaque can
be considered the in vitro model closer to human ﬁbroatheroma
available up to date. Importantly, the present model has the major
limitation to not consider sex, age and genetic predisposition,
which, are in fact, key factors inﬂuencing plaque initiation and
development. In addition, the current model is lacking B and T
lymphocytes that might provide and important contribution in
exacerbating inﬂammation at the plaque level. However, the
participation of cells from the adaptive immune system to plaque
development is still under debate [46,47]. In terms of acellular
components the model is missing calciﬁcation deposits, often
encountered in late-stage plaques. Despite the absence of calciﬁed
areas, calciﬁcation is per-se not a predictor of unstable plaques
(vulnerable plaques) that are prone to rupture and to initiate
ischemic events [48]. The intra-plaque calciﬁcation mechanisms
are tightly regulated by monocyte/macrophages residing within
the plaque [49]. In this regard the 3D plaque model could serve as
basis for both (i) further investigations aimed at uncovering the
mechanisms driving calcium deposition within the atheroma and
(ii) for the biofabrication of more complex and diversiﬁed plaque
models mimicking different stages of atherosclerosis and peculiar
plaque composition.
Despite the ps-plaque model alone cannot address the
complexity of the human vascular environment inwhich wall shear
stress, circulating innate and adaptive immune cells and variations
in LDL cholesterol, blood pressure and diabetes, play a pivotal role
in modulating plaque development, it provides a tool for investi-
gating cellular interplay, viability, metabolism and behavior in a
conﬁned environment sharing anatomopathological features with
human native plaques. The miniaturized plaque can be integrated
in a 96-well or 384-well platform and used for drug design and
screening purposes. Additionally, it can be employed for increasing
the basic understanding of late-stage atherosclerosis disease phe-
nomena including possible anti-inﬂammatory/atheroprotective
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role of HDL, plaque calciﬁcation and rupture or can be integrated in
more complex bioengineered dynamic systems, improving existing
tissue engineered vascular atherosclerosis models [14]. Finally, the
biofabrication process can be applied to blood-derived myeloid
cells isolated from patients with different causative mutations of
familial hypercholesterolemia (FH, life threatening athero-prone
genetic disorder) in order to produce autologous FH-3D models
to identify mutation-dependent differences in plaque architecture,
cellular composition, cell metabolism and viability, with the aim of
predicting mutation-dependent disease prognosis.
Conﬂicts of interest
The authors declare no competing ﬁnancial interest.
Author contributions
A.M. conceived the project and designed the experiments. A.M.
and C.S. established and performed the hanging drop culture ex-
periments. A.M. performed the qPCR, ﬂow cytometry and viability
assays and analyzed the data. Funding for the project were pro-
vided by A.v.E., S.P.H. and B.W.. A.M. wrote the manuscript with the
contribution of C.S., A.v.E., S.P.H. and B.W..
Acknowledgements
This research has been supported by a grant from the 3R
Foundation Switzerland (project No.153-13). We are thankful to the
following individuals and organizations for supporting and
contributing to this work: Christoph Gericke, Group Nitsch Uni-
versity of Zurich, Institute for regenerative medicine, Zurich,
Switzerland; Dr. Chad Brokopp, Mabimmune diagnostics AG;
CABMM, Center for Applied Biotechnology and Molecular Medi-
cine, University of Zurich, Zurich, Switzerland; Zurich Center for
Integrative Human Physiology (ZIHP), University of Zurich, Zurich,
Switzerland; and the Institute of Regenerative Medicine of the
University of Zurich.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.biomaterials.2017.09.034.
References
[1] J.L. Goldstein, M.S. Brown, A century of cholesterol and coronaries: from
plaques to genes to statins, Cell 161 (1) (2015) 161e172.
[2] A. von Eckardstein, Is there a need for novel cardiovascular risk factors?
Nephrol. Dial. Transplant. 19 (4) (2004) 761e765.
[3] J.M. Kelm, M.Y. Emmert, A. Zurcher, D. Schmidt, Y. Begus Nahrmann,
K.L. Rudolph, B. Weber, C.E. Brokopp, T. Frauenfelder, S. Leschka, B. Odermatt,
R. Jenni, V. Falk, G. Zund, S.P. Hoerstrup, Functionality, growth and accelerated
aging of tissue engineered living autologous vascular grafts, Biomaterials 33
(33) (2012) 8277e8285.
[4] K. Yahagi, F.D. Kolodgie, F. Otsuka, A.V. Finn, H.R. Davis, M. Joner, R. Virmani,
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis,
Nat. Rev. Cardiol. 13 (2) (2016) 79e98.
[5] J.F. Bentzon, F. Otsuka, R. Virmani, E. Falk, Mechanisms of plaque formation
and rupture, Circ. Res. 114 (12) (2014) 1852e1866.
[6] R. Virmani, A.P. Burke, F.D. Kolodgie, A. Farb, Pathology of the thin-cap
ﬁbroatheroma: a type of vulnerable plaque, J. Interv. Cardiol. 16 (3) (2003)
267e272.
[7] J.D. Smith, E. Trogan, M. Ginsberg, C. Grigaux, J. Tian, M. Miyata, Decreased
atherosclerosis in mice deﬁcient in both macrophage colony-stimulating
factor (op) and apolipoprotein E, Proc. Natl. Acad. Sci. U. S. A. 92 (18) (1995)
8264e8268.
[8] Y. Kojima, J.P. Volkmer, K. McKenna, M. Civelek, A.J. Lusis, C.L. Miller,
D. Direnzo, V. Nanda, J. Ye, A.J. Connolly, E.E. Schadt, T. Quertermous,
P. Betancur, L. Maegdefessel, L.P. Matic, U. Hedin, I.L. Weissman, N.J. Leeper,
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis,
Nature 536 (7614) (2016) 86e90.
[9] C.A. Reardon, L. Blachowicz, J. Lukens, M. Nissenbaum, G.S. Getz, Genetic
background selectively inﬂuences innominate artery atherosclerosis: immune
system deﬁciency as a probe, Arterioscler. Thromb. Vasc. Biol. 23 (8) (2003)
1449e1454.
[10] J.K. Williams, M.L. Armstrong, D.D. Heistad, Vasa vasorum in atherosclerotic
coronary arteries: responses to vasoactive stimuli and regression of athero-
sclerosis, Circ. Res. 62 (3) (1988) 515e523.
[11] M.L. Armstrong, M.B. Megan, Lipid depletion in atheromatous coronary ar-
teries in rhesus monkeys after regression diets, Circ. Res. 30 (6) (1972)
675e680.
[12] D.J. Graham, J.J. Alexander, R. Miguel, Aortic endothelial and smooth muscle
cell co-culture: an in vitro model of the arterial wall, J. Invest. Surg. 4 (4)
(1991) 487e494.
[13] M. Navab, G.P. Hough, L.W. Stevenson, D.C. Drinkwater, H. Laks,
A.M. Fogelman, Monocyte migration into the subendothelial space of a
coculture of adult human aortic endothelial and smooth muscle cells, J. Clin.
Invest. 82 (6) (1988) 1853e1863.
[14] J. Robert, B. Weber, L. Frese, M.Y. Emmert, D. Schmidt, A. von Eckardstein,
L. Rohrer, S.P. Hoerstrup, A three-dimensional engineered artery model for
in vitro atherosclerosis research, PLos One 8 (11) (2013) e79821.
[15] B. Dorweiler, M. Torzewski, M. Dahm, V. Ochsenhirt, H.A. Lehr, K.J. Lackner,
C.F. Vahl, A novel in vitro model for the study of plaque development in
atherosclerosis, Thromb. Haemost. 95 (1) (2006) 182e189.
[16] K. Menck, D. Behme, M. Pantke, N. Reiling, C. Binder, T. Pukrop, F. Klemm,
Isolation of human monocytes by double gradient centrifugation and their
differentiation to macrophages in teﬂon-coated cell culture bags, J. Vis. Exp.
91 (2014) e51554.
[17] L. Van Der Maaten, G. Hinton, Visualizing high-dimensional data using t-sne.
journal of machine learning research, J. Mach. Learn Res. 9 (2008) 26.
[18] A.D. Amir el, K.L. Davis, M.D. Tadmor, E.F. Simonds, J.H. Levine, S.C. Bendall,
D.K. Shenfeld, S. Krishnaswamy, G.P. Nolan, D. Pe'er, viSNE enables visuali-
zation of high dimensional single-cell data and reveals phenotypic hetero-
geneity of leukemia, Nat. Biotechnol. 31 (6) (2013) 545e552.
[19] M.I. Cybulsky, C. Cheong, C.S. Robbins, Macrophages and dendritic cells:
partners in atherogenesis, Circ. Res. 118 (4) (2016) 637e652.
[20] G. Chinetti-Gbaguidi, S. Colin, B. Staels, Macrophage subsets in atherosclerosis,
Nat. Rev. Cardiol. 12 (1) (2015) 10e17.
[21] K.J. Moore, F.J. Sheedy, E.A. Fisher, Macrophages in atherosclerosis: a dynamic
balance, Nat. Rev. Immunol. 13 (10) (2013) 709e721.
[22] F. Awad, E. Assrawi, C. Jumeau, S. Georgin-Lavialle, L. Cobret, P. Duquesnoy,
W. Piterboth, L. Thomas, K. Stankovic-Stojanovic, C. Louvrier, I. Giurgea,
G. Grateau, S. Amselem, S.A. Karabina, Impact of human monocyte and
macrophage polarization on NLR expression and NLRP3 inﬂammasome acti-
vation, PLos One 12 (4) (2017), e0175336.
[23] M. Peters, K. Dudziak, M. Stiehm, A. Bufe, T-cell polarization depends on
concentration of the danger signal used to activate dendritic cells, Immunol.
Cell Biol. 88 (5) (2010) 537e544.
[24] S. Van Gassen, B. Callebaut, M.J. Van Helden, B.N. Lambrecht, P. Demeester,
T. Dhaene, Y. Saeys, FlowSOM: using self-organizing maps for visualization
and interpretation of cytometry data, Cytom. A 87 (7) (2015) 636e645.
[25] H. Chen, M.C. Lau, M.T. Wong, E.W. Newell, M. Poidinger, J. Chen, Cytofkit: a
bioconductor package for an integrated mass cytometry data analysis pipe-
line, PLoS Comput. Biol. 12 (9) (2016), e1005112.
[26] J. Yang, L. Zhang, C. Yu, X.F. Yang, H. Wang, Monocyte and macrophage dif-
ferentiation: circulation inﬂammatory monocyte as biomarker for inﬂam-
matory diseases, Biomark. Res. 2 (1) (2014) 1.
[27] F. Geissmann, M.G. Manz, S. Jung, M.H. Sieweke, M. Merad, K. Ley, Develop-
ment of monocytes, macrophages, and dendritic cells, Science 327 (5966)
(2010) 656e661.
[28] K.J. Moore, I. Tabas, Macrophages in the pathogenesis of atherosclerosis, Cell
145 (3) (2011) 341e355.
[29] G.J. Randolph, Mechanisms that regulate macrophage burden in atheroscle-
rosis, Circ. Res. 114 (11) (2014) 1757e1771.
[30] E. Bonanno, A. Mauriello, A. Partenzi, L. Anemona, L.G. Spagnoli, Flow
cytometry analysis of atherosclerotic plaque cells from human carotids: a
validation study, Cytometry 39 (2) (2000) 158e165.
[31] K. Kishimoto, G. Tate, T. Kitamura, M. Kojima, T. Mitsuya, Cytologic features
and frequency of plasmacytoid dendritic cells in the lymph nodes of patients
with histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease), Diagn.
Cytopathol. 38 (7) (2010) 521e526.
[32] Y. Doring, H.D. Manthey, M. Drechsler, D. Lievens, R.T. Megens, O. Soehnlein,
M. Busch, M. Manca, R.R. Koenen, J. Pelisek, M.J. Daemen, E. Lutgens, M. Zenke,
C.J. Binder, C. Weber, A. Zernecke, Auto-antigenic protein-DNA complexes
stimulate plasmacytoid dendritic cells to promote atherosclerosis, Circulation
125 (13) (2012) 1673e1683.
[33] N. Macritchie, G. Grassia, S.R. Sabir, M. Maddaluno, P. Welsh, N. Sattar,
A. Ialenti, M. Kurowska-Stolarska, I.B. McInnes, J.M. Brewer, P. Garside,
P. Mafﬁa, Plasmacytoid dendritic cells play a key role in promoting athero-
sclerosis in apolipoprotein E-deﬁcient mice, Arterioscler. Thromb. Vasc. Biol.
32 (11) (2012) 2569e2579.
[34] I. Van Brussel, E.A. Van Vre, G.R. De Meyer, C.J. Vrints, J.M. Bosmans, H. Bult,
Decreased numbers of peripheral blood dendritic cells in patients with cor-
onary artery disease are associated with diminished plasma Flt3 ligand levels
and impaired plasmacytoid dendritic cell function, Clin. Sci. (Lond.) 120 (9)
(2011) 415e426.
A. Mallone et al. / Biomaterials 150 (2018) 49e5958
[35] J.J. Corrales, M. Almeida, R.M. Burgo, P. Hernandez, J.M. Miralles, A. Orfao,
Decreased production of inﬂammatory cytokines by circulating monocytes
and dendritic cells in type 2 diabetic men with atherosclerotic complications,
J. Diabetes Complicat. 21 (1) (2007) 41e49.
[36] V.V. Kunjathoor, M. Febbraio, E.A. Podrez, K.J. Moore, L. Andersson, S. Koehn,
J.S. Rhee, R. Silverstein, H.F. Hoff, M.W. Freeman, Scavenger receptors class A-
I/II and CD36 are the principal receptors responsible for the uptake of
modiﬁed low density lipoprotein leading to lipid loading in macrophages,
J. Biol. Chem. 277 (51) (2002) 49982e49988.
[37] R. Zaguri, I. Verbovetski, M. Atallah, U. Trahtemberg, A. Krispin, E. Nahari,
E. Leitersdorf, D. Mevorach, 'Danger' effect of low-density lipoprotein (LDL)
and oxidized LDL on human immature dendritic cells, Clin. Exp. Immunol. 149
(3) (2007) 543e552.
[38] C.J. Alderman, P.R. Bunyard, B.M. Chain, J.C. Foreman, D.S. Leake, D.R. Katz,
Effects of oxidised low density lipoprotein on dendritic cells: a possible
immunoregulatory component of the atherogenic micro-environment? Car-
diovasc Res. 55 (4) (2002) 806e819.
[39] L. Perrin-Cocon, F. Coutant, S. Agaugue, S. Deforges, P. Andre, V. Lotteau,
Oxidized low-density lipoprotein promotes mature dendritic cell transition
from differentiating monocyte, J. Immunol. 167 (7) (2001) 3785e3791.
[40] B. Feng, P.M. Yao, Y. Li, C.M. Devlin, D. Zhang, H.P. Harding, M. Sweeney,
J.X. Rong, G. Kuriakose, E.A. Fisher, A.R. Marks, D. Ron, I. Tabas, The endo-
plasmic reticulum is the site of cholesterol-induced cytotoxicity in macro-
phages, Nat. Cell Biol. 5 (9) (2003) 781e792.
[41] F.O. Martinez, S. Gordon, M. Locati, A. Mantovani, Transcriptional proﬁling of
the human monocyte-to-macrophage differentiation and polarization: new
molecules and patterns of gene expression, J. Immunol. 177 (10) (2006)
7303e7311.
[42] S. Bekkering, J. Quintin, L.A. Joosten, J.W. van der Meer, M.G. Netea,
N.P. Riksen, Oxidized low-density lipoprotein induces long-term
proinﬂammatory cytokine production and foam cell formation via epige-
netic reprogramming of monocytes, Arterioscler. Thromb. Vasc. Biol. 34 (8)
(2014) 1731e1738.
[43] L.J. van Tits, R. Stienstra, P.L. van Lent, M.G. Netea, L.A. Joosten, A.F. Stalenhoef,
Oxidized LDL enhances pro-inﬂammatory responses of alternatively activated
M2 macrophages: a crucial role for Kruppel-like factor 2, Atherosclerosis 214
(2) (2011) 345e349.
[44] S. Damian-Zamacona, P. Toledo-Ibelles, M.Z. Ibarra-Abundis, L. Uribe-Fig-
ueroa, E. Hernandez-Lemus, K.P. Macedo-Alcibia, B. Delgado-Coello, J. Mas-
Oliva, J.P. Reyes-Grajeda, Early transcriptomic response to LDL and oxLDL in
human vascular smooth muscle cells, PLos One 11 (10) (2016) e0163924.
[45] T.J. Bartosh, J.H. Ylostalo, A. Mohammadipoor, N. Bazhanov, K. Coble,
K. Claypool, R.H. Lee, H. Choi, D.J. Prockop, Aggregation of human mesen-
chymal stromal cells (MSCs) into 3D spheroids enhances their antiin-
ﬂammatory properties, Proc. Natl. Acad. Sci. U. S. A. 107 (31) (2010)
13724e13729.
[46] H.M. Dansky, S.A. Charlton, M.M. Harper, J.D. Smith, T and B lymphocytes play
a minor role in atherosclerotic plaque formation in the apolipoprotein E-
deﬁcient mouse, Proc. Natl. Acad. Sci. U. S. A. 94 (9) (1997) 4642e4646.
[47] F. Cheng, L. Twardowski, K. Reifenberg, K. Winter, A. Canisius, E. Pross, J. Fan,
E. Schmitt, L.D. Shultz, K.J. Lackner, M. Torzewski, Combined B, T and NK cell
deﬁciency accelerates atherosclerosis in BALB/c mice, PLos One 11 (8) (2016)
e0157311.
[48] F. Otsuka, K. Sakakura, K. Yahagi, M. Joner, R. Virmani, Has our understanding
of calciﬁcation in human coronary atherosclerosis progressed? Arterioscler.
Thromb. Vasc. Biol. 34 (4) (2014) 724e736.
[49] Y. Tintut, J. Patel, M. Territo, T. Saini, F. Parhami, L.L. Demer, Monocyte/
macrophage regulation of vascular calciﬁcation in vitro, Circulation 105 (5)
(2002) 650e655.
A. Mallone et al. / Biomaterials 150 (2018) 49e59 59
